GBA PRESENTS- HOUSE OF GUMMY PART 2

72a8e9e8ecc86f0d9732b38c0cd327c5

Vera Therapeutics
  • Presented positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN as a late breaking clinical trial at the 60thERA Congress

  • Initiated Phase 3 ORIGIN 3 clinical trial of atacicept in June for the treatment of IgAN

  • Strong balance sheet expected to fund operations to early 2026
BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business updates and financial results for the second quarter ended June 30, 2023.

“During the second quarter, we announced positive 36-week data from the Phase 2b ORIGIN trial, which support its potential as a disease-modifying treatment for patients with IgAN,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. “We have rapidly advanced atacicept into a pivotal Phase 3 ORIGIN 3 trial in June.”

Second Quarter and Recent Business Highlights

  • Released positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN, which showed both statistically significant and clinically meaningful reduction in proteinuria and stabilization of estimated glomerular filtration rate (eGFR) through 36 weeks. These data were presented as a Late Breaking Clinical Trial at the 60th European Renal Association (ERA) Congress 2023

  • Initiated the pivotal Phase 3 clinical trial (ORIGIN 3) of atacicept for the treatment of IgA nephropathy (IgAN)

  • Strong balance sheet with cash and marketable securities on hand and available credit expected to fund operations to early 2026
Upcoming Milestones

  • Additional data from the ongoing Phase 2b ORIGIN clinical trial to be presented in the second half of 2023 and 2024

  • Expect to announce preliminary data from the pivotal ORIGIN 3 trial in the first half of 2025
 
GOT A BIG ONE-- IF YOU FOLLOW ALONG THE OTHER THREAD YOU KNOW I MARVEL OVER THIS TIDEWATER AND IT'S STRENGTH-- WHY THIS PARTICULAR OIL SERVICES PLAY ALL THE TIME UP EVEN WHEN OTHER ONES ARE NOT? WHAT MAKES TDW SO SPECIAL?-

ichart-98222-930-180-60.png
 
WE HAVE THREE POINTS OF INTEREST & OF SUPPORT RIGHT HERE AT $61<----!!

TDW Tidewater Inc.- THIS MAY BE THE 1ST BUY OF GUMMY 2!

$61.72-0.55 (-0.88%)11:42 AM 08/16/23
NYSE | $USD | Realtime
 
CFO OF VERA BOUGHT 5,000 @ $16.50...

THIS WAS AFTER A SHOOT UP FROM $9 IN JUNE WHEN 1ST RUMBLINGS OF THEIR KIDENEY DISEASE PRODUCT DOING WELL IN TRIALS.

NOT ALL INSIDER BUYING IS THE SAME.. THIS IS THE GOOD KIND. THE STK KEPT GOING TO $19 AND NOW HAS COME IN WE CAN HAVE IT WHERE THE CFO DID-- THAT'S GOOD FOR US!
 
stonedinvestor said:
UPDATE- TDW + $20

NYSE - Nasdaq Real Time Price • USD
Tidewater Inc. (TDW)



$82.61 +12.58 (+17.96%)
As of 1:35 PM EST. Market Open.
More...





GBA SELL TDW $61------------> $91

Tidewater Inc. (TDW)- Tough call here as we don't have any other energy plays except Exxon. But this feels extended and I am not sure we get much higher than this.

Consecutive Winner No 35

$91.67 +0.62 (+0.68%)
As of 10:24 AM EDT. Market Open.
 
stonedinvestor said:
GUMMY 2>

BUY #1-----> SRPT Sarepta Therapeutics, Inc.
$114.23 +1.82 (+1.62%)

BUY #2--->VERA Vera Therapeutics, Inc.
$17.69-0.11(-0.62%)
More...





UPDATE /

VERA has done much better than SRPT: Lets sell them both.

GBA SELL VERA $17-------->$41 :wtf:


VERA Vera Therapeutics, Inc.<------:thumbsup::thumbsup:

$41.980.40(+0.96%)10:28 AM 03/27/24
NASDAQ |$USD |Realtim

No 36


GBA SELL SRPT $114-------> $128 :thumbsdown:

SRPT Sarepta Therapeutics, Inc.- Not counting this towards the record....

$128.270.02(+0.02%)10:31 AM 03/27/24
NASDAQ |$USD |Realtime

GBA SELL SRPT Sarepta Therapeutics, Inc.
 
You must log in or register to reply here.
Back
Top